Pharma BD Deal Intelligence
AstraZeneca PLC / Omthera Pharmaceuticals Inc.
2013 · Acquisition/Merger · $443M · Complete
Announcement Sentiment
25
Negative
AstraZeneca to acquire Omthera for $323M upfront cash + up to $120M dev/approval milestones (total $443M); added NDA-ready Epanova omega-3 dyslipidemia treatment.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
- Announced May 28, 2013
- Closed Jul 18, 2013
- Deal value $443M
- Deal type Acquisition/Merger
- Therapeutic area Severe hypertriglyceridemia / dyslipidemia
- Indications Severe hypertriglyceridemia / dyslipidemia
- Key assets Epanova (omega-3 carboxylic acids)
- Mechanism Free fatty-acid omega-3 (EPA+DHA) lipid-modifying agent
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals